Tislelizumab regimen extends OS in advanced esophageal cancer
The addition of tislelizumab to first-line chemotherapy extended OS among patients with advanced esophageal cancer, according to study results presented at European Society for Medical Oncology World Congress on Gastrointestinal Cancer.The combination conferred a significant survival benefit regardless of PD-L1 status, results of the randomized phase 3 RATIONALE 306 study showed.Tislelizumab (BGB-A317, BeiGene) is a humanized immunoglobulin G4 monoclonal antibody designed to minimize binding to Fc gamma receptors on macrophages, which may result in anti-PD-1 resistance.The double-blindRead More
